BioNeutral Announces U.S. Sales & Distribution Agreement With Quip Laboratories, Inc.
January 21 2014 - 7:45AM
Marketwired
BioNeutral Announces U.S. Sales & Distribution Agreement With
Quip Laboratories, Inc.
NEWARK, NJ--(Marketwired - Jan 21, 2014) - BioNeutral Group,
Inc. (OTCBB: BONU) (OTCQB: BONU) today announced that it has
entered into an Exclusive Distribution Agreement with Quip
Laboratories (Quip) for the market segments of laboratory animal
research and biomedical research. Since 1981, Quip has been a
leader in sales distribution of cleaning and disinfection solutions
to the life science marketplace.
This relationship represents a major step forward to expand our
distribution of our YGIENE™ and OGIENE™ products to these important
life science markets. Through Quip's team of industry experts and
highly trained sales professionals we gain direct access to
decision makers providing us with an opportunity to make an
immediate impact with accounts and applications on the forefront of
scientific research. This arrangement enables BioNeutral products
to become featured within Quip Laboratories' comprehensive
biosafety solutions which, in turn, will streamline the trial and
purchase process among customers seeking to accelerate their
processing times and reduce overall costs.
"Quip Laboratories is very pleased to add BioNeutral products to
our roster of innovative biosafety product technologies for which
we are renowned," said Quip Laboratories President, Tim Hidell.
"Throughout our three decades of growth, our clients have come to
rely on us for breakthrough products that address their facility
hygiene challenges," he continued. "This exclusive partnership
leverages Quip's leadership in the biosafety industry as well as
BioNeutral's product excellence in product innovation and
performance. We are proud of this partnership," Hidell said, "and
we are confident that the addition of the BioNeutral products to
our portfolio will facilitate their broad adoption across North
America."
"This exclusive partnership is a major component of our market
specific channel and distribution strategy. This agreement
entrenches BioNeutral in the life sciences industry with one of the
dominant players. Quip has a history of being on the forefront of
developing and introducing new, innovative technologies to the
biosafety industry," said Ray Dunning, Senior Vice President of
Sales for BioNeutral. "Additionally, this gives us the ability to
support Quip's experienced team and diverse customer base, while
expanding their product line with a high performing
sporicide/sterilant offering the unique capabilities that are in
greater demand today."
About Quip Laboratories, Inc.
Based in Wilmington, DE and founded in 1981, Quip Laboratories
focuses on providing sanitation solutions to Life Science and Food
Processing sectors. Their state-of-the-art manufacturing facility
produces proprietary chemicals that have enabled the company to
achieve a leadership position in the markets served. Featuring
in-house research and development, production, quality control and
sales and marketing, Quip provides a "total-systems" approach to
providing efficient and eco-gentle environment hygiene. Find Quip
at www.quiplabs.com.
About BioNeutral Group, Inc.
Headquartered in Newark, New Jersey, BioNeutral Group, Inc., is
a specialty technology-based life-science company that has
developed a technology platform that neutralizes harmful
environmental contaminants, toxins and dangerous micro-organisms
including bacteria, viruses, mold, fungi and spores. BioNeutral's
products, YGIENE™ and OGIENE™, kill germs and clean surfaces with a
dramatic increase in speed and power over their rivals in the
marketplace. BioNeutral's proprietary platform technology has been
proven effective in surface, water and airborne applications. Its
antimicrobial line of products under the Ygiene™ brand have been
approved by the EPA for sale in the United States and has
previously been approved for sale in Germany and it is also
permitted to be sold in the UK, France and Sweden. For more
information on BioNeutral, including a listing of company products,
leadership and background please visit www.bioneutral.com.
Find us on Facebook:
http://www.facebook.com/pages/BioNeutral-Group/149109938452393
Follow us on Twitter: http://twitter.com/bioneutralgroup
Forward-Looking Statements: This release contains
certain "forward-looking statements" relating to the business of
the Company and its subsidiary companies. These forward-looking
statements are often identified by the use of forward-looking
terminology such as "believes," "expects" or similar expressions.
Such forward-looking statements involve known and unknown risks and
uncertainties that may cause actual results to be materially
different from those described herein as anticipated, believed,
estimated or expected. Investors should not place undue reliance on
these forward-looking statements, which speak only as of the date
of this press release. The Company's actual results could differ
materially from those anticipated in these forward-looking
statements as a result of a variety of factors, including those
described in the Company's filings with the Securities and Exchange
Commission. BioNeutral routinely tests its formulations against
those of its competitors. The results are published to let
shareholders know how the Company's technology compares with known
formulations in the market place. Any product claim for
antimicrobial activity requires approval from the EPA or FDA,
depending upon where and how the formulations are used. The EPA has
approved and registered the Company's data and findings specific to
Ygiene-206. BioNeutral's antimicrobial formulations will be
marketed under the brand name Ygiene® and are available for sale in
the United States.
CONTACT: FOR THE COMPANY: Mark Lowenthal CEO BioNeutral Group,
Inc. +1-973-577-8003